The medial director of Novartis talked about findings from a real-world study assessing ofatumumab treatment for multiple sclerosis presented at the 2024 ACTRIMS Forum. [WATCH TIME: 3 minutes]
Jason Freeman, MD, MBA
Advertisement
Articles by Jason Freeman, MD, MBA
Jason Freeman, MD, MBA, and Abby Rogers, DMSc, PA-C, MPAS, discuss a study presented at ACTRIMS 2023 on high-efficacy disease-modifying therapies for treatment-naïve patients with multiple sclerosis. Sponsored by Novartis.
Jason Freeman, MD, MBA, and Gina Mavrikis Cox, PhD, discuss a presentation from CMSC 2023 on the role of serum biomarkers in multiple sclerosis management. Sponsored by Novartis.
Advertisement
Latest Updated Articles
FDA Approves Lecanemab Autoinjector, Marking First At-Home Treatment for Alzheimer DiseasePublished: August 29th 2025 | Updated: September 2nd 2025
Indirect Comparison Study Hints at Lower ARIA and ICH-Related Mortality Risk in Lecanemab Over DonanemabPublished: July 28th 2025 | Updated: July 30th 2025
Observed Differences in PIRA Definition Call for More Standardized Agreement on TermPublished: May 14th 2025 | Updated: May 16th 2025
Serum Neurofilament Light Chain Limited in Predicting MOGAD Attacks but Correlates With Attack SeverityPublished: May 12th 2025 | Updated: May 13th 2025
- FDA Approves Diazoxide Choline Extended-Release Tablets for Hyperphagia in Prader-Willi Syndrome
Published: March 27th 2025 | Updated: March 28th 2025
BTK Inhibitor Tolebrutinib Shows Greater Effectiveness in Multiple Sclerosis with Higher Paramagnetic Rim Lesion CountsPublished: March 4th 2025 | Updated: March 19th 2025
Advertisement
Advertisement
Trending on NeurologyLive
1
Stem Cells of Secondary Progressive Multiple Sclerosis Drive Increased Proinflammatory T-Cell Activity
2
EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits
3
Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
4
Postmortem Analysis Reveals Distinct Patterns of Aquaporin-4 in Parkinson Disease and Multiple System Atrophy
5
